A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma

F. Dagnaes-Hansen, L. M. Rasmussen, Ronald Tilton, Larry Denner, A. Flyvbjerg

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A number of studies have provided indirect evidence that angiogenesis is involved in tumour growth and metastasis formation of renal cell carcinoma (RCC). Nude mice bearing xenografts of human Caki-I RCC were treated i.p. for 3 weeks with a murine monoclonal antibody against vascular endothelial growth factor, VEGF (VEGF-ab). Tumour growth and mRNA expression of human and murine VEGF and murine VE-Cadherin in the tumours were measured. After 3 weeks of therapy, the tumour volume in the control nude mice was 548 ± 98 mm3 compared to the tumours in the nude mice treated with VEGF-ab (122 ± 24 mm3, p < 0.01). Treatment with VEGF-ab significantly reduced mRNA expression of murine VEGF-120 and murine VE-Cadherin (p < 0.05 and p < 0.01, respectively). The mRNA expression of human VEGF (hVEGF165, hVEGF189) and murine VEGF (mVEGF164) was unchanged due to antibody treatment. The mean percentage of apoptotic cells in tumours harvested from antibody-treated animals was significantly lower than in tumours from the control-treated animals (p < 0.02). These findings demonstrate for the first time that VEGF-ab significantly inhibit the growth of Caki-I RCC in vivo.

Original languageEnglish
Pages (from-to)1625-1630
Number of pages6
JournalAnticancer Research
Volume23
Issue number2 B
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Antibodies
Growth
Nude Mice
Neoplasms
Messenger RNA
Neoplasm Antibodies
Tumor Burden
Heterografts
Monoclonal Antibodies
Neoplasm Metastasis

Keywords

  • Experimental kidney neoplasms
  • mRNA
  • Renal cell carcinoma
  • Vascular endothelial growth factor
  • VE-Cadherin
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dagnaes-Hansen, F., Rasmussen, L. M., Tilton, R., Denner, L., & Flyvbjerg, A. (2003). A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma. Anticancer Research, 23(2 B), 1625-1630.

A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma. / Dagnaes-Hansen, F.; Rasmussen, L. M.; Tilton, Ronald; Denner, Larry; Flyvbjerg, A.

In: Anticancer Research, Vol. 23, No. 2 B, 03.2003, p. 1625-1630.

Research output: Contribution to journalArticle

Dagnaes-Hansen, F, Rasmussen, LM, Tilton, R, Denner, L & Flyvbjerg, A 2003, 'A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma', Anticancer Research, vol. 23, no. 2 B, pp. 1625-1630.
Dagnaes-Hansen, F. ; Rasmussen, L. M. ; Tilton, Ronald ; Denner, Larry ; Flyvbjerg, A. / A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma. In: Anticancer Research. 2003 ; Vol. 23, No. 2 B. pp. 1625-1630.
@article{d68a25421aee4627b410dfa2cfc8f1ef,
title = "A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma",
abstract = "A number of studies have provided indirect evidence that angiogenesis is involved in tumour growth and metastasis formation of renal cell carcinoma (RCC). Nude mice bearing xenografts of human Caki-I RCC were treated i.p. for 3 weeks with a murine monoclonal antibody against vascular endothelial growth factor, VEGF (VEGF-ab). Tumour growth and mRNA expression of human and murine VEGF and murine VE-Cadherin in the tumours were measured. After 3 weeks of therapy, the tumour volume in the control nude mice was 548 ± 98 mm3 compared to the tumours in the nude mice treated with VEGF-ab (122 ± 24 mm3, p < 0.01). Treatment with VEGF-ab significantly reduced mRNA expression of murine VEGF-120 and murine VE-Cadherin (p < 0.05 and p < 0.01, respectively). The mRNA expression of human VEGF (hVEGF165, hVEGF189) and murine VEGF (mVEGF164) was unchanged due to antibody treatment. The mean percentage of apoptotic cells in tumours harvested from antibody-treated animals was significantly lower than in tumours from the control-treated animals (p < 0.02). These findings demonstrate for the first time that VEGF-ab significantly inhibit the growth of Caki-I RCC in vivo.",
keywords = "Experimental kidney neoplasms, mRNA, Renal cell carcinoma, Vascular endothelial growth factor, VE-Cadherin, VEGF",
author = "F. Dagnaes-Hansen and Rasmussen, {L. M.} and Ronald Tilton and Larry Denner and A. Flyvbjerg",
year = "2003",
month = "3",
language = "English",
volume = "23",
pages = "1625--1630",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma

AU - Dagnaes-Hansen, F.

AU - Rasmussen, L. M.

AU - Tilton, Ronald

AU - Denner, Larry

AU - Flyvbjerg, A.

PY - 2003/3

Y1 - 2003/3

N2 - A number of studies have provided indirect evidence that angiogenesis is involved in tumour growth and metastasis formation of renal cell carcinoma (RCC). Nude mice bearing xenografts of human Caki-I RCC were treated i.p. for 3 weeks with a murine monoclonal antibody against vascular endothelial growth factor, VEGF (VEGF-ab). Tumour growth and mRNA expression of human and murine VEGF and murine VE-Cadherin in the tumours were measured. After 3 weeks of therapy, the tumour volume in the control nude mice was 548 ± 98 mm3 compared to the tumours in the nude mice treated with VEGF-ab (122 ± 24 mm3, p < 0.01). Treatment with VEGF-ab significantly reduced mRNA expression of murine VEGF-120 and murine VE-Cadherin (p < 0.05 and p < 0.01, respectively). The mRNA expression of human VEGF (hVEGF165, hVEGF189) and murine VEGF (mVEGF164) was unchanged due to antibody treatment. The mean percentage of apoptotic cells in tumours harvested from antibody-treated animals was significantly lower than in tumours from the control-treated animals (p < 0.02). These findings demonstrate for the first time that VEGF-ab significantly inhibit the growth of Caki-I RCC in vivo.

AB - A number of studies have provided indirect evidence that angiogenesis is involved in tumour growth and metastasis formation of renal cell carcinoma (RCC). Nude mice bearing xenografts of human Caki-I RCC were treated i.p. for 3 weeks with a murine monoclonal antibody against vascular endothelial growth factor, VEGF (VEGF-ab). Tumour growth and mRNA expression of human and murine VEGF and murine VE-Cadherin in the tumours were measured. After 3 weeks of therapy, the tumour volume in the control nude mice was 548 ± 98 mm3 compared to the tumours in the nude mice treated with VEGF-ab (122 ± 24 mm3, p < 0.01). Treatment with VEGF-ab significantly reduced mRNA expression of murine VEGF-120 and murine VE-Cadherin (p < 0.05 and p < 0.01, respectively). The mRNA expression of human VEGF (hVEGF165, hVEGF189) and murine VEGF (mVEGF164) was unchanged due to antibody treatment. The mean percentage of apoptotic cells in tumours harvested from antibody-treated animals was significantly lower than in tumours from the control-treated animals (p < 0.02). These findings demonstrate for the first time that VEGF-ab significantly inhibit the growth of Caki-I RCC in vivo.

KW - Experimental kidney neoplasms

KW - mRNA

KW - Renal cell carcinoma

KW - Vascular endothelial growth factor

KW - VE-Cadherin

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0037562497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037562497&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1625

EP - 1630

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -